

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5240169

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	HERRIOT TABUTEAU	12/01/2017
RECEIVING PARTY DATA		
Name:	ANTECIP BIOVENTURES II LLC	
Street Address:	630 FIFTH AVENUE, SUITE 2000	
City:	NEW YORK	
State/Country:	NEW YORK	
Postal Code:	10111	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	16133553	
CORRESPONDENCE DATA		
Fax Number:	(435)252-1361	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	949-202-1900	
Email:	Docket@mabr.com	
Correspondent Name:	BRENT A. JOHNSON	
Address Line 1:	MASCHOFF BRENNAN	
Address Line 2:	100 SPECTRUM CENTER DRIVE, SUITE 1200	
Address Line 4:	IRVINE, CALIFORNIA 92618	
ATTORNEY DOCKET NUMBER:	A3226.10002US44	
NAME OF SUBMITTER:	MARIA NADAL	
SIGNATURE:	/Maria Nadal/	
DATE SIGNED:	11/15/2018	
Total Attachments: 9		
source=12-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page1.tif		
source=12-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page2.tif		
source=12-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page3.tif		
source=12-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page4.tif		
source=12-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page5.tif		

source=12-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page6.tif
source=12-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page7.tif
source=12-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page8.tif
source=12-2017 - EXECUTED ASSIGNMENT Tabuteau to Antecip#page9.tif

ASSIGNMENT

THIS ASSIGNMENT is made by **Herriot Tabuteau** (hereafter, together with any successors, legal representatives, or assigns thereof, "ASSIGNOR") to **Antecip Bioventures II LLC**, a legal entity having its principal place of business at 630 Fifth Avenue, Suite 2000, New York, New York 10111 (hereafter, together with any successors, legal representatives, or assigns thereof, "ASSIGNEE").

WHEREAS, ASSIGNOR has invented and owns rights in, to and under new and useful inventions for which an application(s) for or Letters Patent has been filed as indicated on **Exhibit A** (hereafter "Inventions");

WHEREAS, ASSIGNOR believes himself to be the original and true inventor of the Inventions;

WHEREAS, ASSIGNEE desires to acquire the Inventions and improvements thereto;

AND WHEREAS, ASSIGNOR and ASSIGNEE desire to have a recordable instrument assigning ASSIGNEE as owners of the entire right, title and interest in, to, and under the Inventions and improvements thereto owned by ASSIGNOR;

NOW THEREFORE, for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR does hereby sell, assign, transfer, convey, endorse, and hereby set over unto ASSIGNEE the full and exclusive right, title and interest in, to and under the Inventions to be held and enjoyed by ASSIGNEE, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment and sale not been made including the full and exclusive right, title and interest in, to and under 1) any patent application, or any other legal instrument equivalent thereof, including, without limitation, continuation, division, continuation-in-part, substitute, reexamination, renewal, inventor's certificate, and utility model, which has been or may be submitted therefor and thereon anywhere in the World, such term defined herein as including the United States of America, its territorial possessions, and any and all foreign countries under national laws or under the provisions of the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, or any other international treaty equivalent thereof; 2) any Letters Patent, or any other legal instrument equivalent thereof, which has been or may be granted therefor and thereon, in the World, for the full term or terms for which the same may be granted; 3) any reissue, extension, or any other legal instrument equivalent thereof, on any patent application or Letters Patent which has been or may be granted therefor and thereon in the World; and 4) any right to claim priority to a filing date, or any other legal equivalent thereof, which has been or may be claimed by any patent application or Letters Patent therefor and thereon in the World.

ASSIGNOR hereby covenants and agrees to perform any lawful action when deemed essential by and to ASSIGNEE's full enjoyment, protection, enforcement and title in, to and under the Inventions and rights hereby transferred, including, but not limited to, promptly communicating and providing any and all known and accessible facts, data or any other pertinent information; promptly executing and delivering any and all papers, documents, forms, declarations, oaths, affidavits or any other legal instrument; promptly assisting and participating in any and all depositions, hearings, proceedings, trials, appeals, or any other legal procedure; promptly testifying under oath in any and all interference, post grant review, litigation or any other


administrative or judicial proceeding; and promptly completing any and all actions necessary or desirable to carry out any and all purposes thereof, relating to any and all proceedings in connection with the submission, procurement, issuance, maintenance, enforcement or defense of the inventions and rights hereby transferred.

A Notary Public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached and not the truthfulness accuracy or validity of that document.

IN TESTIMONY WHEREOF, I hereunder set my hand this 1 day of Dec., 2017.

ASSIGNOR

Herriot Tabuteau


Signature

State of)
County of) ss.:

On this ____ day of _____, 2017, before me, _____, personally appeared **Herriot Tabuteau**, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.


Witness my hand and official seal.

Notary Public

A Notary Public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached and not the truthfulness accuracy or validity of that document.

ACKNOWLEDGED AND CONFIRMED, I hereunder set my hand this 1 day of Dec, 2017, as a duly authorized representative of ASSIGNEE.

ASSIGNEE


Name: Herriot Tabuteau, MD
Title: Managing Member

State of _____)
County of _____) ss.:

On this _____ day of _____, 2017, before me, _____, personally appeared **Herriot Tabuteau** who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

Witness my hand and official seal.

Notary Public

EXHIBIT A**Patent Rights: Patents and Patent Applications**

<u>Title</u>	<u>Serial No.</u>	<u>Filing Date</u>
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/446,971	01 Mar 2017
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	15/454,874	09 Mar 2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/459,992	15 Mar 2017
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	PCT/US2017/024140	24 Mar 2017
OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	15/481,330	06 Apr 2017
OSTEOCLAST INHIBITORS SUCH AS ZOLEDRONIC ACID FOR LOW BACK PAIN TREATMENT	15/484,766	11 Apr 2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/498,251	26 Apr 2017

<u>Title</u>	<u>Serial No.</u>	<u>Filing Date</u>
NERIDRONIC ACID MOLECULAR COMPLEX FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/587,246	04 May 2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/587,108	04 May 2017
PHARMACEUTICAL COMPOSITIONS COMPRISING FROVATRIPTAN	62/504,105	10 May 2017
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	15/599,163	18 May 2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/599,319	18 May 2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/604,394	24 May 2017
METHODS FOR THE SAFE ADMINISTRATION OF IMIDAZOLE OR IMIDAZOLIUM COMPOUNDS	15/605,730	25 May 2017
COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	15/619,293	09 Jun 2017
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC	15/621,882	13 Jun 2017

<u>Title</u>	<u>Serial No.</u>	<u>Filing Date</u>
EFFECTS		
COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN	15/623,274	14 Jun 2017
OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	15/624,471	15 Jun 2017
OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	15/624,428	15 Jun 2017
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	15/645,939	10 Jul 2017
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	15/647,069	11 Jul 2017
CO-ADMINISTRATION OF STEROIDS AND ZOLEDRONIC ACID TO PREVENT AND TREAT PAIN	15/647,140	11 Jul 2017
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	15/647,852	12 Jul 2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/672,147	08 Aug 2017

<u>Title</u>	<u>Serial No.</u>	<u>Filing Date</u>
COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	15/672,126	08 Aug 2017
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	15/688,660	28 Aug 2017
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	15/691,532	30 Aug 2017
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	15/691,549	30 Aug 2017
COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS FOR SUSTAINED DELIVERY OF DEXTROMETHORPHAN	15/695,995	05 Sep 2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/697,267	06 Sep 2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING ANKYLOSING SPONDYLITIS	15/697,211	05 Sept 2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/702,616	12 Sep 2017
OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	15/703,891	13 Sep 2017

<u>Title</u>	<u>Serial No.</u>	<u>Filing Date</u>
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/707,673	18 Sep 2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING ARTHRITIS	15/707,238	18 Sep 2017
NERIDRONIC ACID FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/710,759	20 Sep 2017
OSTEOCLAST INHIBITORS FOR JOINT CONDITIONS	15/716,334	26 Sep 2017
CO-ADMINISTRATION OF STEROIDS AND ZOLEDRONIC ACID TO PREVENT AND TREAT PAIN	15/782,480	12 Oct 2017
COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOWER BACK PAIN	15/787,612	18 Oct 2017
BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTION	62/576,538	24 Oct 2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/801,049	01 Nov 2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/801,028	01 Nov 2017
NERIDRONIC ACID FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/804,781	06 Nov 2017

<u>Title</u>	<u>Serial No.</u>	<u>Filing Date</u>
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/806,236	07 Nov 2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/808,794	09 Nov 2017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/814,745	16 Nov 2017
NERIDRONIC ACID FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/820,305	21 Nov 2017
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	15/821,563	22 Nov 2017